Maxim Group began coverage on shares of Kintara Therapeutics (NASDAQ:KTRA) in a report issued on Friday, TipRanks reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price target points to a potential upside of 106.90% from the company’s current price.
Separately, Aegis reissued a “buy” rating and set a $6.00 price target on shares of Kintara Therapeutics in a research report on Thursday, October 1st.
NASDAQ:KTRA opened at $1.45 on Friday. The stock has a 50-day moving average of $1.48. Kintara Therapeutics has a 12 month low of $0.38 and a 12 month high of $1.95. The stock has a market cap of $35.76 million, a PE ratio of -1.65 and a beta of 1.82.
A hedge fund recently bought a new stake in Kintara Therapeutics stock. IPG Investment Advisors LLC purchased a new stake in shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 26,000 shares of the company’s stock, valued at approximately $36,000. IPG Investment Advisors LLC owned 0.11% of Kintara Therapeutics at the end of the most recent reporting period. 2.14% of the stock is currently owned by hedge funds and other institutional investors.
About Kintara Therapeutics
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.